top of page


Roche licenses Rona Therapeutics ALK7-targeting RNAi obesity therapy in deal worth up to $1.16 billion
Roche has secured worldwide rights to Rona Therapeutics' investigational ALK7-targeting RNAi therapy in an obesity and metabolic disease licensing agreement worth up to $1.16 billion.

nuaxia
Oct 152 min read


Zealand Pharma signs AI protein therapeutics collaboration with Generate Biomedicines worth over $1 billion
Zealand Pharma and Generate Biomedicines have signed an AI-enabled protein therapeutics collaboration for obesity and metabolic diseases with potential milestone payments approaching $1.2 billion.

nuaxia
Oct 152 min read


Zealand Pharma begins Phase 3 ZUPREME programme for petrelintide in obesity
Zealand Pharma and Roche have started the global Phase 3 ZUPREME programme evaluating once-weekly petrelintide as a treatment for people with overweight or obesity.

nuaxia
Sep 242 min read


Roche’s Genentech licenses Hanmi obesity candidate HM17321 in deal worth up to $2.3 billion
The agreement gives Genentech ex-South Korea rights to a Phase I non-incretin UCN2 analogue designed to reduce weight while preserving lean body mass, adding a differentiated mechanism to Roche’s growing cardiometabolic pipeline.

nuaxia
Aug 253 min read


Kalohexis Files Confidentially for IPO to Advance Obesity and Cachexia Pipeline
The clinical-stage biotech plans to use a potential public listing to accelerate development of melanocortin-based therapies targeting obesity and cancer cachexia.

nuaxia
Jul 93 min read


Lilly’s Oral GLP-1 Foundayo Wins FDA Approval, Intensifying Obesity Drug Market Competition
New oral weight-loss treatment enters the market as competition with Novo Nordisk’s oral Wegovy accelerates.

nuaxia
Apr 21 min read


NMPA Approves Ecnoglutide for Chronic Weight Management in Adults with Overweight or Obesity
China authorises the first cAMP-biased GLP-1 receptor agonist for obesity, following robust Phase III SLIMMER trial results.

nuaxia
Mar 91 min read
bottom of page